ERBB2 and neoplasm: Therefore, a pharmacologic screening using Ru1–Ru10 were performed in a panel of representative tumor cell lines of each subtype: luminal (RH+/HER2−:T47D and MCF7) and HER2+ (BT474 and SKBR3) (Figure 4A).